Navigation Links
Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
Date:3/12/2008

Prove-it Herpes Offers Considerable Cost Savings for Healthcare Industry by

Identifying Eight Herpesviruses Simultaneously

HELSINKI, Finland, March 12 /PRNewswire/ -- The Finland-based biotechnology company Mobidiag today announced the new Prove-it(TM) Herpes test for the fast and reliable identification of herpesviruses. The microarray-based test takes less than three hours to complete and enables simultaneous identification of eight different human herpesviruses. Herpesviruses cause life-threatening central nervous system infections (CNSI), and rapid diagnosis improves likelihood of recovery. The new test is initially intended for research purposes, and Mobidiag plans to acquire European approval for use in clinical diagnostics later this year.

"Market potential for the product is enormous. In Europe alone, over 100 million euros are spent annually on herpesvirus diagnostics. We believe that Prove-it(TM) Herpes will gain a considerable slice of that market," says Jaakko Pellosniemi, CEO of Mobidiag. "What makes Prove-it(TM) Herpes unique is that it combines different technologies and integrates them into a single easy-to-use and capable product," Pellosniemi continues.

In addition to illnesses such as labial herpes, chickenpox and roseola, herpesviruses can also cause serious central nervous system infections such as encephalitis. Without appropriate treatment, mortality rate from these infections can be as high as 50%. The sooner the pathogen is detected, the higher the likelihood of recovery. However, virus detection may be slow with current methods, and in severe suspected virus infection cases, medication is often started merely as a precaution. There are roughly four million of these suspected cases annually in the Industrial World, making testing and treating potential infections very expensive.

The Mobidiag test can detect and identify the viruses many times faster than conventional methods. Appropriate antiviral treatment can be administered sooner, and the level of potential permanent damage to the patient is decreased. Additionally, Mobidiag's test reveals multi-infections caused by several herpesviruses. The detection is also exceptionally sensitive to low viral loads, which are typical in the early stages of a central nervous system infection.

"We believe that in the future, microarray-based tests will quickly become common in diagnostics due to their simplicity, speed, and reliability. A clinician can instantly check hundreds of viral and bacterial-based illnesses, offering a huge saving potential for the healthcare industry. Mobidiag will play a vital role in this development," says Pellosniemi.

Founded in 2001, Mobidiag develops rapid diagnostic tests for hospital laboratories. The Prove-it(TM) Herpes test is developed in co-operation with Hospital Districts of Helsinki and Uusimaa and the University of Helsinki.

Additional information:

Mobidiag Ltd is a Finnish biotechnology company developing, producing and marketing rapid diagnostic tests to hospital laboratories. The company focuses on detection of serious infections with DNA-tests. More information on http://www.mobidiag.com

- Press photos from http://www.mobidiag.com/media/images

- CEO Jaakko Pellosniemi, Mobidiag Ltd, tel. +358-40-501-1004

- Press contact, Ville Lehtovirta, +358-50-346-6946, ville.lehtovirta@conexio.fi


'/>"/>
SOURCE Mobidiag Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
2. BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services
3. MIGENIX releases CEO message #22
4. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
5. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
6. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
7. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
8. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
9. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
10. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
11. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  An international ... of Medicine and St. Boniface Hospital Albrechtsen Research ... peripheral neuropathy, an unmet health need affecting nearly ... Journal of Clinical Investigation, their results identify small ... prevent and reverse neuronal injury in animal models ...
(Date:1/17/2017)... LEXINGTON, Mass. , Jan. 17, 2017   ... clinical stage biopharmaceutical company developing innovative inhaled therapies to ... candidate for treating fungal infections in the lungs of ... Infectious Disease Product" (QIDP) by the U.S. Food & ... , which is designed to speed the development of ...
(Date:1/17/2017)... 17, 2017  Only nine percent of U.S. consumers ... while only 16 percent believe health insurance companies do, ... 36 percent of U.S. adults believe health care providers ... compared to hospitals (23%). "We are in ... Wendy Salomon , vice president of reputation management and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Pono Ola , a mind-body wellness firm ... today the official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue ... development for over a year, the patented Pono Board is the world’s only exercise ...
Breaking Biology Technology:
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)... -- For the thousands of attendees at this year,s International Consumer Electronics Show ... biometric measurement devices and services, will be featuring its new line of ... Medical,s special CES Exhibit Suite , the new upper arm and ... WellnessConnected product platform.  Continue ... ...
Breaking Biology News(10 mins):